Get our Free Patent Expiration Newsletter

Serving hundreds of leading biopharmaceutical companies globally:

Julphar
Colorcon
Express Scripts
Johnson and Johnson
Chinese Patent Office
Merck

Generated: August 19, 2019

DrugPatentWatch Database Preview

Claims for Patent: 8,216,571

  Try a free trial


See Plans and Pricing

« Back to Dashboard

Summary for Patent: 8,216,571
Title:Fully human anti-VEGF antibodies and methods of using
Abstract: Disclosed herein are fully human antibodies and antigen-binding fragments thereof that specifically bind human VEGF and inhibit VEGF binding to VEGF-R1 and VEGF-R2, and therefore inhibit VEGF signaling. The antibodies and antigen-binding fragments disclosed herein may be used, for example, to treat angiogenesis and conditions associated with angiogenesis both in vivo and in vitro.
Inventor(s): Ramachandra; Sumant (Northbrook, IL), Bishop; Walter Robert (Pompton Plains, NJ), Masat; Linda (Walnut Creek, CA), Huang; Chao Bai (San Leandro, CA), Takeuchi; Toshihiko (Oakland, CA), Kantak; Seema (Pacifica, CA), Huang; Chin-Yi (Fremont, CA)
Assignee: Schering Corporation (Kenilworth, NJ)
Application Number:12/739,383
Patent Claims:1. An isolated antibody or antigen-binding fragment thereof that specifically binds VEGF and comprises a light chain immunoglobulin comprising CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 12, CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 13 and CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 14 and a heavy chain immunoglobulin comprising CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 6, CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 7 and CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 17.

2. The antibody or antigen-binding fragment thereof as recited in claim 1, comprising a light chain immunoglobulin comprising the amino acid sequence set forth in SEQ ID NO:5; and a heavy chain immunoglobulin comprising the amino acid sequence set forth in SEQ ID NO:22.

3. The antibody or antigen-binding fragment thereof as recited in claim 1, wherein the antibody or antigen-binding fragment thereof is selected from the group consisting of a monoclonal antibody, a polyclonal antibody, a chimeric antibody, a humanized antibody, a recombinant antibody, a fully human antibody, a bivalent antibody, an anti-idiotypic antibody, a camelized single domain antibody, a diabody, a scFv, an scFv dimer, a dsFv, a (dsFv).sub.2, a dsFv-dsFv', an Fv fragment, a Fab, a Fab', a F(ab').sub.2, a ds diabody, a nanobody, a domain antibody, and a bivalent domain antibody.

4. The antibody or antigen-binding fragment thereof as recited in claim 1, further comprising an immunoglobulin constant region selected from the group consisting of a .kappa. light chain, a .gamma.1 heavy chain, a .gamma.2 heavy chain, a .gamma.3 heavy chain, and a .gamma.4 heavy chain constant region.

5. The antibody or antigen-binding fragment thereof as recited in claim 1, wherein said antibody or antigen-binding fragment inhibits tumor growth as a function of percent tumor growth inhibition to the same or a greater degree than Bevacizumab when administered at a dosage selected from the group consisting of two-fold lower, three-fold lower, four-fold lower, and five-fold lower than Bevacizumab.

6. The antibody or antigen-binding fragment thereof as recited in claim 1, wherein said antibody or antigen-binding fragment inhibits tumor growth to a specified size for a time period selected from the group consisting of at least twice the duration of Bevacizumab and at least three times the duration of Bevacizumab when administered at the same or a lower dosage than Bevacizumab.

7. The antibody or antigen-binding fragment thereof as recited in claim 1, wherein said antibody or antigen-binding fragment binds to an epitope on human VEGF.sub.165 that overlaps at least partially with the epitope bound by Bevacizumab.

8. The antibody or antigen-binding fragment thereof as recited in claim 1, wherein said antibody or antigen-binding fragment blocks binding of human VEGF.sub.165 to VEGF-R1 and VEGF-R2.

9. The antibody or antigen-binding fragment thereof as recited in claim 1, wherein said antibody or antigen-binding fragment binds human VEGF.sub.165 with a K.sub.D that is at least 10-fold, at least 50-fold or at least 100-lower than the K.sub.D of said antibody or antigen-binding fragment for binding to murine VEGF.sub.165.

10. A pharmaceutical composition comprising the antibody or antigen-binding fragment thereof as recited in claim 1 and one or more antioxidants.

11. A pharmaceutical composition comprising the antibody or antigen-binding fragment thereof as recited in claim 1 and one or more pharmaceutically acceptable carriers.

12. The pharmaceutical composition of claim 10, wherein said one or more antioxidants are selected from the group consisting of methionine, ascorbic acid, EDTA, sodium thiosulfate, platinum, catalase, citric acid, cysteine, thioglycerol, thioglycolic acid, thiosorbitol, butylated hydroxanisol, butylated hydroxytoluene, and/or propyl gallate.

13. A pharmaceutical composition comprising the antibody or antigen-binding fragment thereof as recited in claim 1 in combination with one or more additional chemotherapeutic agents selected from the group consisting of capecitabine, a combination of irinotecan, 5-fluorouracil and leucovorin, carboplatin, leucovorin, oxaliplatin and 5-fluorouracil.

14. A complex comprising an antibody or antigen-binding fragment thereof as recited in claim 1 bound to human VEGF.sub.165 or a fragment of human VEGF.sub.165.

15. An isolated polypeptide comprising one or more amino acid sequences selected from the group consisting of SEQ ID NOs:5 and 22.

16. A method of inhibiting angiogenesis in a human subject in need thereof comprising administering to said subject a therapeutically effective amount of the antibody or antigen-binding fragment thereof as recited in claim 1, optionally linked to or in combination with one or more additional chemotherapeutic agents.

17. A method of treating a disease associated with aberrant angiogenesis in a human subject in need thereof comprising administering to said subject a therapeutically effective amount of the antibody or antigen-binding fragment thereof as recited in claim 1, optionally linked to or in combination with one or more additional chemotherapeutic agents.

18. A method of treating an inflammatory disease associated with VEGF signaling in a human subject in need thereof comprising administering to said subject a therapeutically effective amount of the antibody or antigen-binding fragment thereof as recited in claim 1, optionally linked to or in combination with one or more additional chemotherapeutic agents, wherein said disease is rheumatoid arthritis.

19. A method of treating wet acute macular degeneration or diabetic retinopathy in a human subject in need thereof comprising administering to said subject a therapeutically effective amount of the antibody or antigen-binding fragment thereof as recited in claim 1.

20. A method of treating a cancer associated with increased VEGF signaling in a human subject in need thereof comprising administering to said subject a therapeutically effective amount of the antibody or antigen-binding fragment thereof as recited in claim 1, optionally in combination with one or more additional chemotherapeutic agents, wherein said cancer is breast cancer.

21. A kit comprising the antibody or antigen-binding fragment thereof as recited in claim 1 and instructions for the use of said antibody or antigen-binding fragment.

Summary for Patent:   Try a Free Trial

PCT Information
PCT FiledOctober 20, 2008PCT Application Number:PCT/US2008/080531
PCT Publication Date:April 30, 2009PCT Publication Number:WO2009/055343

Details for Patent 8,216,571

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Genentech AVASTIN bevacizumab VIAL; INTRAVENOUS 125085 001 2004-02-26   Try a Free Trial Schering Corporation (Kenilworth, NJ) 2027-10-22 RX search
Genentech AVASTIN bevacizumab VIAL; INTRAVENOUS 125085 002 2004-02-26   Try a Free Trial Schering Corporation (Kenilworth, NJ) 2027-10-22 RX search
Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source

Subscribe to access the full database, or try a Free Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

US Army
Queensland Health
Chubb
UBS
Accenture
Medtronic

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.